Captrust Financial Advisors Novo Cure LTD Transaction History

Captrust Financial Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$56.6 - $89.9 $2,999 - $4,764	-53 Reduced 4.1%	1,239 $86,000
Q2 2022 Aug 16, 2022	BUY	$56.6 - $89.9 $23,375 - $37,128	413 Added 46.99%	1,292 $90,000
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $7,578 - $10,649	126 Added 16.73%	879 $73,000
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $750 - $1,219	-10 Reduced 1.31%	753 $57,000
Q3 2021 Nov 16, 2021	SELL	$116.17 - $194.55 $51,347 - $85,991	-442 Reduced 36.68%	763 $89,000
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $110,970 - $191,968	851 Added 240.4%	1,205 $267,000
Q1 2021 May 17, 2021	BUY	$124.11 - $190.17 $33,385 - $51,155	269 Added 316.47%	354 $47,000
Q3 2020 Nov 17, 2020	SELL	$58.05 - $111.31 $8,301 - $15,917	-143 Reduced 62.72%	85 $10,000
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $13,041 - $16,965	228 New	228 $14,000
Q4 2019 Feb 14, 2020	SELL	$68.3 - $93.8 $35,242 - $48,400	-516 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$61.86 - $97.8 $9,279 - $14,670	150 Added 40.98%	516 $39,000
Q2 2019 Aug 13, 2019	BUY	$42.22 - $63.23 $15,452 - $23,142	366 New	366 $23,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.07B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.